• Practical Lip Vol 1 Issue 4 Cover Image
  • CME

  • Practical Lipidology: Volume 1, Number 4

  • Author(s)/Faculty: Michael H. Davidson, MD, FACC, FACP, FNLA; Peter H. Jones, MD, FACP, FNLA; Carl E. Orringer, MD, FACC, FNLA; Peter P. Toth, MD, PhD, FAAP, FNLA, FAHA, FACC; Benjamin J. Ansell, MD, FACC, FACP, FNLA; Alan S. Brown, MD; James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA; Gregory S. Pokrywka, MD, FACP, FNLA, NCMP; Thomas Dayspring, MD, FACP, FNLA
    Source: Cardiology Today
    Type: Journal Articles/Items: 10
    Release Date: 5/1/2012 Expiration Date: 5/1/2013
    Credit Type: CME Number of Credit(s): 1.25
    Cost: Free Provider: Vindico Medical Education

  • Dyslipidemia management has traditionally focused on controlling elevated low-density lipoprotein cholesterol (LDL-C) levels. However, several recent trials have highlighted the importance of non-LDL lipid parameters, such as high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG), as important targets for cardiovascular risk modification. On the strength of these data, medical societies are embracing atherosclerotic markers other than LDL-C as important targets for treatment in patients with dyslipidemia.

Sponsorship Statement: This continuing medical education activity is jointly sponsored by Vindico Medical Education and CT_logosm_EduLabs.gif

Support Statement: This activity is supported by an educational grant from genentech_sm.gif

Target Audience: The intended audience for this activity is cardiologists, internists, lipidologists, and other healthcare professionals involved in the treatment of patients at risk for cardiac events.

Learning Objectives:  At the conclusion of this series, participants should be able to:

  • Assess screening procedures and risk stratification techniques to identify patients at risk for coronary heart disease.
  • Apply new clinical evidence and guidelines for primary and secondary prevention in patients with lipid disorders.
  • Evaluate emerging lipid-modifying therapies that favorably alter lipid metabolism; prevent, slow, or reverse atherogenesis; and lower cardiovascular risk.
  • Examine the correlation between cardiovascular events and low levels of HDL and analyze current research and understanding on the role of the HDL receptors and the mechanisms underlying HDL function, metabolism and production.
  • Integrate strategies to evaluate HDL based on the interpretation of clinical data, to effectively manage HDL and decrease cardiovascular risk and overall atherosclerosis development.
  • Tailor lipid treatment approaches to the particular needs of specific patient populations, including those with comorbid diseases.
  • Implement patient-centered approaches that increase compliance and adherence to therapeutic regimens to improve cardiovascular health and patient health literacy.
  • Define atherogenic dyslipidemia and employ methods into practice to diagnose and treat the disorder promptly.

Chief Medical Editor:
Michael H. Davidson, MD, FACC,FACP, FNLA
Editorial Board Member, CHD and Prevention
Cardiology Today®
Clinical Professor
Director of Preventive Cardiology
University of Chicago Pritzker School of Medicine
Chicago, IL

Editorial Board:
Peter H. Jones, MD, FACP, FNLA
Associate Professor
Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, TX

Carl E. Orringer, MD, FACC, FNLA
Harrington-McLaughlin Chair in Preventive Cardiovascular Medicine
University Hospitals Case Medical Center
Associate Professor of Medicine
Case Western Reserve University School of Medicine
Cleveland, OH

Peter P. Toth, MD, PhD, FAAP, FNLA, FAHA, FACC
Director of Preventive Cardiology
CGH Medical Center
Clinical Professor
University of Illinois
Peoria, IL

Contributing Faculty:
Alan S. Brown, MD, FACC FACP, FNLA
Medical Director, Midwest Heart Disease Prevention Center
Interventional Cardiologist, Midwest Heart Specialists
Clinical Associate Professor of Medicine
Loyola University Stritch School of Medicine
Naperville, IL

Benjamin J. Ansell, MD, FACC, FCCP, FAHA
Co-Director, UCLA Cholesterol, Hypertension & Atherosclerosis
Management Program
Professor, Department of Medicine
Division of General Internal Medicine and Cardiology
UCLA School of Medicine
Los Angeles, CA

Thomas D. Dayspring, MD, FACP, FNLA
Director of Cardiovascular Education
The Foundation for Health Improvement and Technology
Richmond, VA

Clinical Assistant Professor of Medicine
University of Medicine and Dentistry of New Jersey
New Jersey Medical School
Newark, NJ

Gregory S. Pokrywka, MD, FACP, FNLA, NCMP
Director
Baltimore Lipid Center
Baltimore, MD

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Clinical Assistant Professor of Medicine
NYU School of Medicine & NYU Langone Center for Cardiovascular Disease Prevention
Director
Bellevue Hospital Lipid Clinic
New York, NY

Accreditation:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and Cardiology Today®. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, May 1, 2012 to May 1, 2013.

How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 out of 10 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.

External Reviewer:
William J. Howard, MD

Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Planning Committee and Faculty members report the following relationship(s):
Benjamin J. Ansell, MD, FACC FACP, FNLA
Consulting Fees: Pfizer, Genentech
Fees for Non-CME Services: Pfizer
Ownership Interest: Bruin Pharma, Amgen

Alan S. Brown, MD
Consulting Fees: Abbott, Kowa
Fees for Non-CME Services: Abbott, Kowa, Daiichi-Sankyo

Michael H. Davidson, MD, FACC, FACP, FNLA
Speakers’ Bureau: Abbott, AstraZeneca, GlaxoSmithKline, Merck
Advisory Board/Consultant: Abbott, Aegerion, Amgen, AstraZeneca, Atherotech, Daiichi Sankyo, DTC MD, Esperion, GlaxoSmithKline, iMD (Intelligent Medical
Decisions), Kinemed, LipoScience, Merck, NovoNordisk, Roche, sanofi-aventis, Synarc, Takeda, Vindico Medical Education
Grant/Research: Abbott, Daiichi Sankyo, GlaxoSmithKline, Merck, Roche
Board of Directors: DTC MD, Omthera, Professional Evaluation, Inc. Medical Education Company, Sonogene

Thomas Dayspring, MD, FACP, FNLA
Consulting Fees: Abbott Labs, GlaxoSmithKline, Health Diagnostic Labs, Kowa/Eli Lilly, Merck, Genentech: The Roche Group, Genzyme, Omthera
Lecture Bureau: Abbot Labs, GlaxoSmithKline, Health Diagnostic Labs, Kowa/Eli Lilly, LipoScience, Merck

Gregory S. Pokrywka, MD, FACP, FNLA, NCMP
Fees for Non-CME Services: AstraZeneca, DSI, HDL, KOWA, Lilly, LipoScience, Metagenics

Peter H. Jones, MD, FACP
Consulting Fees: Abbott, Merck, Genentech, Atherotech
Fees for Non-CME Services: Abbott, Merck, AstraZeneca

Carl E. Orringer, MD, FACC, FNLA
No relevant financial relationships to disclose.

Peter P. Toth, MD, PhD, FAAP, FNLA, FAHA, FACC
Consulting Fees: Abbott, AstraZeneca, Genzyme, Genentech, Merck
Fees for Non-CME Services: Abbott, AstraZeneca, GlaxoSmithKline, Takeda, Merck, Pfizer, Boehringer Ingelheim

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Consulting Fees: Genzyme, LipoScience, Daiichi Sankyo, Abbott, Kowa
Fees for Non-CME Services: Abbott, Merck, Kowa, Eli Lilly, Daiichi Sankyo, Forest, GlaxoSmithKline, LipoScience
Contracted Research: Kowa

External reviewer reports the following relationship(s):
William J. Howard, MD
Consulting Fees: Merck
Fees for Non-CME Services: Merck, Abbott, GlaxoSmithKline

Vindico Medical Education and Cardiology Today® staff report the following relationship(s):
No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-848-1000; Fax: 856-848-6091. Printed in the USA. Copyright © 2012 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and Cardiology Today® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and Cardiology Today®. Neither Vindico Medical Education, Cardiology Today®, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Vindico Medical Education:
Medical Director
Ronald Codario, MD, FACP, FNLA

Director of Medical Education
Chris Rosenberg

Managing Editor
Jill Rollet

Program Manager
Darla Thompson

Publication Design
Kimi Dolan and David Barker